The effects of subcutaneous administration of 10, 30, or 100 μg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial. The plasma glucose response to a Sustacal test meal was significantly reduced compared with placebo both after 1 week and after 2 weeks of administration of 30 or 100 μg pramlintide. In addition, 24-h mean plasma glucose concentrations were significantly lowered in patients receiving 30 μg of pramlintide for 2 weeks compared with placebo, while the 100-μg pramlintide dose did not reach statistical significance for the 24-h glucose profiles. At 10 μg, pramlintide had no effect on the 24-h glucose profile or on the plasma glucose response to a Sustacal test meal. The reduction in 24-h glucose concentrations and glucose concentrations after the Sustacal test meal observed at the 30-μg pramlintide dose was not accompanied by an increased incidence of hypoglycemic events. The most frequent adverse events were dose-related and involved transient upper gastrointestinal symptoms. A majority (>80%) of the patients who reported these adverse events during week 1 did not report them in week 2. These data indicate that pramlintide effectively reduces plasma glucose concentrations as reflected in both a 24-h glucose profile and a Sustacal test meal while maintaining an acceptable safety profile.
Skip Nav Destination
Article navigation
Original Articles|
April 01 1997
Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial
Robert G Thomas;
Robert G Thomas
Amylin Pharmaceuticals, Inc
San Diego, California
Search for other works by this author on:
Janet Peterson;
Janet Peterson
Amylin Pharmaceuticals, Inc
San Diego, California
Search for other works by this author on:
Alan Gottlieb;
Alan Gottlieb
Amylin Pharmaceuticals, Inc
San Diego, California
Search for other works by this author on:
John Mullane
John Mullane
Amylin Pharmaceuticals, Inc
San Diego, California
Search for other works by this author on:
Address correspondence and reprint requests to Dr. Robert G. Thompson, Amylin Pharmaceuticals, Inc., 9373 Towne Centre Dr., San Diego, CA 92121.
1
AUC, area under the curve; Cmax, 24-h maximum glucose concentration; Cmin, 24-h minimum glucose concentration; DCCT, Diabetes Control and Complications Trial.
Diabetes 1997;46(4):632–636
Article history
Received:
April 15 1996
Revision Received:
November 07 1996
Accepted:
November 07 1996
Citation
Robert G Thomas, Janet Peterson, Alan Gottlieb, John Mullane; Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial. Diabetes 1 April 1997; 46 (4): 632–636. https://doi.org/10.2337/diab.46.4.632
Download citation file:
46
Views